Matthew F Hudson

Dr. Matthew F Hudson

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 October 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
CACasey J. Allen
Casey J. Allen
RSRebecca A. Snyder
Rebecca A. Snyder
DHDanea Marie Horn
Danea Marie Horn
MHMatthew F Hudson
Matthew F Hudson
ABAnne Barber
Anne Barber
RGRachel A. Greenup
Rachel A. Greenup
PURPOSE: We determine how stakeholders prioritize the importance of oncologic outcomes, patient-reported outcomes (PROs), and cancer-related health care costs. METHODS: A survey was distributed to the National Clinical Trials Network Alliance for Clinical Trials in Oncology cooperative group membership from May 14 to June 30, 2022. Respondents were asked to rate (5-point Likert scale) and rank (1-9) evidence-based value domains: overall survival, treatment toxicities/complications, quality of life (QOL), financial toxicity, access to care, compliance with evidence-based care, health system performance, scientific discovery and innovation, and cost to the health care system. RESULTS: A total of 514 members responded, including researchers (24.7%), nurses (19.5%), medical oncologists (17.9%), administrators (9.3%), surgical and radiation oncologists (9.1%), patient advocates (3.1%), and nonphysician providers (16.4%). Participants represented various practice settings including National Cancer Institute–designated cancer centers (29.8%), university-affiliated academic cancer centers (21%), hospital-owned oncology practices (21.8%), and others (27.4%). There was agreement in how respondents prioritized value domains (W = 0.39, P < .001). Respondents ranked patient QOL (mean rank: 2.6 ± 1.9) as most important above all other metrics including survival (mean rank: 3.5 ± 0.3) and access to care (mean rank: 3.5 ± 2.1; P < .001). Members engaged in direct patient care also ranked access to care of higher importance than nonclinicians ( P = .026). Cost to the health care system (mean rank: 7.5 ± 2.1) and health system performance (mean rank: 7 ± 2) were ranked as least important ( P < .001). Inclusion of PROs into therapeutic assessment (59.3%) was the most frequently selected priority of future cooperative group initiatives. CONCLUSION: Oncology community stakeholders deemed patient-centered value domains as most important and considered patient QOL the highest priority. Inclusion of PROs into clinical trials was endorsed as an important component of therapeutic assessment. These findings can be taken into consideration when creating a value framework for inclusion in cancer clinical trials.

16 May 2025 in Journal of Participatory Medicine
Verified
Journal Article
Open access
SWSusan S Woods
Susan S Woods
SGSarah M Greene
Sarah M Greene
LALaura Adams
Laura Adams
GCGrace Cordovano
Grace Cordovano
MHMatthew F Hudson
Matthew F Hudson
Artificial intelligence (AI) and large language models offer significant potential to enhance many aspects of daily life. Patients and caregivers are increasingly using AI for their own knowledge and to address personal challenges. The growth of AI has been extraordinary; however, the field is only beginning to explore its intersection with participatory medicine. For many years, the Journal of Participatory Medicine has published insights on tech-enabled patient empowerment and strategies to enhance patient-clinician relationships. This theme issue, Patient and Consumer Use of AI for Health, will explore the use of AI for health from the perspective of patients and the public.

17 June 2022 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
JBJason J Bischof
Jason J Bischof
MEMohamed I. I Elsaid
Mohamed I. I Elsaid
JBJohn F.P. Bridges
John F.P. Bridges
ARAshley Rosko
Ashley Rosko
CPCarolyn J. Presley
Carolyn J. Presley
JCJeffrey M. Caterino
Jeffrey M. Caterino

22 November 2021 in Academic Emergency Medicine
Verified
Journal Article
Closed access
PDF file
AKAdam D. Klotz
Adam D. Klotz
JCJeffrey M. Caterino
Jeffrey M. Caterino
DDDanielle Durham
Danielle Durham
JRJuan Felipe Rico
Juan Felipe Rico
DPDaniel J. Pallin
Daniel J. Pallin
CBChristopher W. Baugh
Christopher W. Baugh

Keith NorrisKeith Norris
Keith Norris
MHMatthew F Hudson
Matthew F Hudson
MWM. Wilson
M. Wilson
GWGenevieve L. Wojcik
Genevieve L. Wojcik
Elizabeth O. OfiliElizabeth O. Ofili
Elizabeth O. Ofili
JHJerris R Hedges
Jerris R Hedges
Health professionals commonly reference race and ethnicity to inform health care and administrative decisions. However, health researchers (and, arguably, society at large) misapply race and ethnicity when assuming an inherent relationship of these concepts with biological and health outcomes of interest. Misapplication of race potentially results from socially embedded identification predicated upon race essentialism, the belief that people within a racial group share “inherent” biological traits that define them as distinct from other racial groups. This false belief is often associated with implied racial hierarchies obscuring authentic causal disease relationships. Similarly, ethnicity is a socially and politically constructed group descriptor for people from a similar national or regional background who may share common cultural, historical, and social experiences. Thus, as for race, no inherent biological information is contained within such group definitions. This article summarizes the Research Centers for Minority Institutions (RCMI) 2025 Annual Grantee Meeting keynote session on Race and Ethnicity in Medicine. The session described how society originated and subsequently applied/misapplied race and ethnicity in various domains of policy and public health. The keynote session also considered the use of race and ethnicity in describing and envisioning biomedical research, clinical trials, clinical practice, and health services research. The authors summarize a more tenable use of race and ethnicity to advance biomedical research and health by focusing upon social and environmental drivers of health, population representation in clinical trials, and other factors. Associated recommendations from the keynote session are provided.